Prime Medicine, Inc. (PRME)
Prime Medicine, Inc. (PRME) from its SEC filings: 2025 revenue $4.6 million (+55% vs the year before), net margin -4342%, free cash flow -$167.1 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $4.6 million |
| Revenue growth | +55% |
| Net income | -$201.1 million |
| Net margin | -4342.4% |
| Free cash flow | -$167.1 million |
| Diluted EPS | $-1.35 |
| Latest quarter (Q3 2025 (calendar)) revenue vs a year earlier | +486% |
| Cash | $47.5 million |
| Share count, 1 year | +35% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.